Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure
Condition(s):Non-Squamous Non-Small Cell Lung CancerLast Updated:March 28, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Non-Squamous Non-Small Cell Lung CancerLast Updated:March 28, 2024Recruiting
Condition(s):Patients Suffering From Solid TumorsLast Updated:March 28, 2024Completed
Condition(s):COVID-19Last Updated:March 28, 2024Recruiting
Condition(s):Cardiac Arrest, Out-Of-HospitalLast Updated:March 28, 2024Not yet recruiting
Condition(s):Healthy Volunteer EGEA4 CohortLast Updated:March 28, 2024Recruiting
Condition(s):Nephrotic SyndromeLast Updated:March 28, 2024Not yet recruiting
Condition(s):Burns; PruritusLast Updated:March 28, 2024Recruiting
Condition(s):Daily Step Count; MASLD; BMI; Metabolic Syndrome; NAFLD; Insulin Resistance; Genetic Polymorphism; Cardiovascular Disease (CVD)Last Updated:March 28, 2024Not yet recruiting
Condition(s):Healthy Volunteers Only; Energy MetabolismLast Updated:March 28, 2024Not yet recruiting
Condition(s):Sleep DisorderLast Updated:March 28, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.